In Brief
Metabolism regulates macrophage activation. Sanin et al. demonstrate that in IL-4-activated macrophages, PGE2 induces changes in the expression of malate-aspartate shuttle genes, which in turn leads to changes in mitochondrial membrane potential and triggers alterations in chromatin accessibility and ETV1-dependent changes in expression of a gene set that includes Retnla.
INTRODUCTION
Changes in metabolism are intrinsic to, and required for, immune cell activation (Buck et al., 2016; O'Neill and Pearce, 2016) . When macrophages are exposed to lipopolysaccharide (LPS) and interferon-g (IFN-g) or to interleukin-4 (IL-4), they undergo major and largely non-overlapping changes in gene expression and exhibit distinct metabolic profiles dominated by aerobic glycolysis (Warburg metabolism) or augmented oxidative phosphorylation (OXPHOS), respectively. In both cases, inhibition of the dominant metabolic pathway inhibits the activation response (Buck et al., 2016; O'Neill and Pearce, 2016) .
Consistent with their broad roles in tissue biology during homeostatic conditions, infection, cancer, and traumatic damage, macrophages express a range of receptors that allow them to respond to exogenous signals and assume distinct functions (Amit et al., 2016) . Differing gene expression profiles under this spectrum of stimulatory conditions have been defined (Xue et al., 2014) , but little is known about whether metabolism is fine-tuned to support and enable these various activation states. In this context, we have been interested in alternatively activated macrophages, a term that was originally used to describe macrophages activated via the IL-4 receptor (M2 or M(IL-4) macrophages) but has since evolved to include cells stimulated through other pathways (Ginhoux et al., 2016) . For example, a variety of reports indicate that PGE2 can, both independently and in concert with IL-4, promote alternative activation (Luan et al., 2015; Na et al., 2015) . PGE2 is implicated in cancer development (Zelenay et al., 2015) , and it also suppresses the production of inflammatory cytokines in LPS-activated macrophages (Tang et al., 2017) . Moreover, PGE2 plays positive roles in the maintenance of gastric mucosal integrity (Miyoshi et al., 2017) , immunity to Mycobacterium tuberculosis (Mayer-Barber et al., 2014) , and the prevention of fibrosis (Harada et al., 2017) . Consequently, we were interested in whether PGE2 would accentuate or modify the metabolic profile of M(IL-4) macrophages as it relates to gene expression in these cells.
Increased OXPHOS, a hallmark of M(IL-4) cells, is intimately linked to mitochondrial membrane potential (Dc m ). In mitochondria, potential across the inner mitochondrial membrane is established as the electron transport chain (ETC) exports protons from the matrix into the intermembrane space, providing the motive force for ATP synthesis. The activity of the tricarboxylic acid (TCA) cycle, the availability of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH 2 ) to fuel the ETC, and the expression of uncoupling proteins provide physiologic mechanisms for regulating Dc m . Recent work has identified additional roles for Dc m , beyond ATP synthesis, in mitochondrial reactive oxygen species (ROS) and cellular proliferation (Martí-nez-Reyes et al., 2016) , acetylation of mitochondrial matrix proteins (Yang et al., 2016) , and stemness and longevity of CD8 + T cells (Sukumar et al., 2016) . Thus, Dc m is linked to different cell fates.
Here, we found that macrophages co-stimulated with IL-4 plus PGE2 exhibited altered gene expression accompanied by changes in metabolism, which included a marked decrease in Dc m . Diminished Dc m was induced by changes in the malateaspartate shuttle (MAS), a mitochondrial pathway that regulates redox balance. We discovered a Dc m -sensitive gene program regulated largely by the transcription factor (TF) ETV1. ETV1-controlled ''voltage-regulated genes'' (VRGs) included Retnla, a key marker of alternative activation, and genes involved in the cell cycle, which could explain the observed PGE2-induced reductions in cellular proliferation. Thus, by exploring an unappreciated facet of PGE2 biology, we have identified a Dc mdependent mechanism of mitochondria-nucleus communication in which nuclear gene expression is regulated by Dc m -dependent control of ETV1.
RESULTS

PGE2 Modifies Alternative Macrophage Activation
In light of existing evidence indicating that PGE2 can promote alternative activation both independently and in concert with IL-4 (Luan et al., 2015; Na et al., 2015) , we set out to study the transcriptome of macrophages exposed to this lipid mediator. In mouse bone-marrow-derived macrophages (BMMs), PGE2 induced the expression of some genes associated with alternative-M(IL-4)-cell activation, including Arg1, Il4ra, and Clec10a (CD301) ( Figure 1A) . However, other genes encoding markers of M(IL-4) macrophages, such as Retnla (RELMa), Cd36, Chil3, Mrc1, and Pparg, were not induced. Indeed, most genes regulated by PGE2 were not related to M(IL-4) cell activation (Figures S1A and S1B). Nevertheless, PGE2 accentuated IL-4-induced expression of Arg1, IL4ra, Clec10a, CD36, and Mrc1 ( Figure 1B ) when both stimuli where used simultaneously (co-stimulation), although it suppressed the expression of Retnla and Pparg ( Figure 1B) . Examination of CD301 and RELMa expression by flow cytometry confirmed that IL-4-induced markers can be accentuated or suppressed by PGE2 ( Figure 1C ). PGE2 did not alter IL-4-induced phosphorylation of STAT6 ( Figure 1D ) (Gordon and Martinez, 2010) . Thus, PGE2 has marked STAT6-independent effects on M(IL-4) cell activation.
Metabolic reprogramming intrinsically regulates macrophage function (O'Neill and Pearce, 2016) . Therefore, we asked whether PGE2-induced changes in M(IL-4) macrophages reflect alterations in metabolism. Elevated baseline oxygen-consumption rates (OCRs), maximal respiration, and glycolytic reserve are markers of M(IL-4) macrophages (Huang et al., 2014) , and each was diminished by PGE2 ( Figures 1E, 1F , and S1C-S1E). Consistent with this, PGE2 caused decreased glucose 13 C incorporation into TCA cycle intermediates ( Figure 1G) ; this was not a reflection of reduced glucose uptake ( Figure S1F ) or of altered activity of phosphofructokinase 1 (PFK1) (Rider et al., 2004) (Figure S1G ) and could not readily be explained by changes in the expression of genes involved in glycolysis, the TCA cycle, or OXPHOS ( Figure S1H ). These metabolic changes were associated with reduced cellular ATP ( Figure 1H ) and diminished cytoplasmic and mitochondrial ROS ( Figures 1I and 1J ), overall indicating that PGE2 has a dampening effect on mitochondrial metabolism. The development of Dc m is critical for mitochondrial function, and we reasoned that this parameter might also be affected. Using tetramethylrhodamine methyl ester (TMRM), we found that Dc m of macrophages treated with IL-4 plus PGE2 was lower than that of M(IL-4) cells ( Figure 1K ).
PGE2 Modulates Mitochondrial Membrane Potential
We found that effects of PGE2 on Dc m developed between 2 and 4 hr after stimulation and intensified thereafter (Figures 2A, S2A , and S2B). Diminished Dc m can presage cell death (Gottlieb and Bernstein, 2016) , but M(IL-4) macrophages treated with PGE2 survived normally in culture (Figures 2B and S2C) . Moreover, the mitochondrial-unfolded-protein response, an indicator of mitochondrial damage (Gottlieb and Bernstein, 2016) , was not induced by PGE2 given that expression of Hspd1, Hspa9, and Dnaja3 was diminished rather than increased ( Figure 2C ). Reduction in Dc m was not a reflection of reduction in mitochondrial mass, as measured by the amount of TOM20 or MitoTracker staining ( Figures 2D and S2D ). Decreased Dc m can lead to mitochondrial fission (Willems et al., 2015) , but mitochondria remained elongated in M(IL-4) cells plus PGE2 ( Figure 2E ), and we found no evidence of proteolytic cleavage of the long isoform of OPA1 ( Figure S2E ), which is required for fission (Willems et al., 2015) . Furthermore, ultrastructural examination revealed no pathological changes in M(IL-4) treated with PGE2 but did show that cristae were narrower in M(IL-4) than in M(-) and that this difference was lost once the M(IL-4) macrophages were co-stimulated with PGE2 ( Figures 2F and 2G ), a finding that is consistent with the observed differences in maximal respiration in these cells ( Figure 1E ) and our understanding of the relationship between maximal respiration and cristae morphology (Buck et al., 2016) . Thus, PGE2 reduced Dc m independently of effects on viability or major alterations in mitochondrial content or morphology.
We further examined the effects of PGE2 on Dc m. We found that a PGE2-induced reduction in Dc m was also apparent in peritoneal macrophages (pMacs) stimulated with IL-4 (Figure 2H) . Moreover, the ability of PGE2 to affect macrophage Dc m was not dependent on IL-4-induced events because Dc m in M(À) macrophages was also reduced by PGE2 ( Figure S2F ). Nor was it restricted to murine macrophages, given that the same was true for human peripheral-blood monocytes cultured with PGE2 ( Figure S2G ). However, PGE2 had no effect on Dc m when it was used to co-stimulate M(LPS+IFN-g) ( Figure S2H ).
Overall, our data indicate that PGE2 diminishes Dc m in respiring cells and that although this is associated with reduced OXPHOS, it is not an indicator of mitochondrial damage.
Changes in Dc m Result from Altered Mitochondrial Shuttle Activity
We wanted to understand the basis of the effect of PGE2 on Dc m . We reasoned that cAMP, which is induced by PGE2 (Rodríguez et al., 2014) , could play a role in diminished Dc m . We found that either 8-Br-cAMP, a membrane permeable form of cAMP, or the cAMP-inducer forskolin recapitulated the effects of PGE2 in lowering Dc m and cellular ATP concentration while suppressing RELMa and increasing CD301 expression in M(IL-4) macrophages ( Figures S3A and S3B ). On the other hand, PKA inhibition increased Dc m ( Figure S3C ). Thus, PGE2-induced changes in Dc m are most likely mediated by cAMP. Dc m is established by the transport of protons from the mitochondrial matrix into the inter-membrane space by ETC complexes I (CI), III (CIII), and IV (CIV). However, we detected no overall decrease in expression of ETC complexes after PGE2 treatment (Figure S3D) . We next determined whether dysfunction at one of the complexes is responsible for PGE2-induced changes in Dc m . In permeabilized macrophages, we found that CI inhibition with rotenone decreased Dc m , whereas subsequently providing succinate for CII restored Dc m comparably in both M(IL-4) cells and M(IL-4) cells treated with PGE2 (Figure 3A) . Moreover, CIII inhibition with antimycin abrogated Dc m ( Figure 3A ) in both types of activated macrophages. These data indicate that PGE2 does not affect the activity of CI, CII, or CIII and imply that CI and CIII are equally capable of generating Dc m in M(IL-4) macrophages with or without PGE2. Next, we asked whether inhibiting CV, which should increase Dc m by preventing the dissipation of the proton gradient to generate ATP, would allow an equivalent increase in Dc m in the presence or absence of PGE2. We found that Dc m increased more rapidly in M(IL-4) cells treated with PGE2 than in M(IL-4) cells without PGE2 (Figures 3B and S3E) . The rapid increase in Dc m as a result of CV inhibition in PGE2-treated cells could be consistent with heightened ATP demand, which would lead to decreased ATP in these cells ( Figure 1H ). We addressed this by pharmacologically increasing ATP in the cells ( Figure S3F ) by assuming that if Dc m was depleted by heightened ATP demand, an increase in ATP would remove this constraint. However, increasing ATP had no effect on Dc m ( Figure S3G ). We (legend continued on next page) actively limit Dc m without negatively affecting individual complex activity.
The timing of PGE2 effects on Dc m ( Figure 2A ) was consistent with induced transcriptional changes rather than direct causative biochemical events. To explore this, we measured Dc m in M(IL-4) macrophages with or without PGE2 when transcription was inhibited by a-amanitin (a-A) ( Figure S3H ) and found that PGE2 had no effect on Dc m ( Figure 3C ). We next searched for gene expression changes that could account for reduced Dc m by focusing on mitochondrial solute carriers as candidates that modulate Dc m . We found no effect of PGE2 on the expression of Slc25a5, Slc25a4, or Ucp2, which encode proteins capable of dissipating Dc m ( Figure 3D ) (Woyda-Ploszczyca and Jarmuszkiewicz, 2017). However, we noted a reduction in expression of Slc25a13 in M(IL-4) macrophages treated with PGE2 ( Figure 3D ). This gene encodes a component of the MAS, a system that facilitates redox balance between mitochondria and the cytoplasm ( Figure 3E ). Because early reports linked MAS to Dc m (Kauppinen et al., 1987) , we reasoned that MAS function might be altered after PGE2 treatment. Indeed, PGE2 caused changes in expression of many of the MAS genes ( Figure 3F ) and reductions in overall cellular amounts of the MAS metabolites glutamate (Glu), aspartate (Asp), and NAD + at early and late times after stimulation ( Figure 3G ). We next evaluated NADH mitochondrial shuttling by tracing the transfer of a deuterium from glucose (Glc), through glyceraldehyde 3 phosphate (G3P) and NADH, into malate (Mal) ( Figure 3H ) (Lewis et al., 2014) . Our data show that M(IL-4) macrophages with or without PGE2 took up similar amounts of 2 H-Glc and comparably reduced pyruvate to lactate ( Figure 3I ). However, NADH incorporation into Mal was diminished in response to PGE2 ( Figure 3I ). Our data indicate that MAS activity was changed by PGE2, suggesting that this shuttle could regulate Dc m after PGE2 treatment. If altered MAS function underlies the effects of PGE2, then changes in MAS gene expression should occur before the loss of Dc m . Indeed, expression of Got1 and Slc25a13 was altered by PGE2 shortly after treatment ( Figure S3I ). We then hypothesized that the effects of PGE2 should be reversed by loss of function of GOT1, the amount of which is increased in response to PGE2 (Figures 3F and S3I) . Consistent with this, we found that Got1-shRNA-mediated suppression of GOT1 expression (Figure S3J ) reversed the inhibitory effects of PGE2 on Dc m (Figure 3J ) and also increased Dc m in M(IL-4) macrophages that had not been treated with PGE2, suggesting a broader regulatory role for the MAS in M(IL-4) cell biology.
Together, our data indicate that reduced Dc m downstream of PGE2 reflects changes in the expression of genes encoding mitochondrial redox shuttles and associated changes in shuttle activity and point to the MAS as being instrumental in the regulation of Dc m under these conditions. Dc m Controls the Expression of a Set of Nuclear Genes Mitochondria are signaling hubs (Chandel, 2015) , and we questioned whether PGE2-mediated changes in IL-4-induced gene expression are functionally related to diminished Dc m . To separate the effects of changes in Dc m from transcriptional regulation induced by PGE2 signaling, we used low-dose valinomycin (Val), a K + ionophore that collapses Dc m without affecting plasmamembrane permeability or viability ( Figure S4A ). We added Val to macrophages that had been stimulated 4 hr earlier with IL-4 in order to initiate loss of Dc m at approximately the time it occurs after PGE2 addition ( Figure 2A ) and compared changes in gene expression in these cells 2 hr later with those induced 6 hr after IL-4 and PGE2 co-stimulation ( Figure 4A ). We reasoned that there would be common changes in gene expression in cells treated with IL-4 and PGE2 or with IL-4 and Val, so we compared each group of cells with IL-4-treated macrophages ( Figure 4B ) or with resting macrophages ( Figure 4C ). In this latter comparison, we excluded changes in gene expression seen in cells treated with IL-4, again by using resting macrophages as a baseline. In this manner, we identified 126 voltage-regulated genes (VRGs) that had a significant >2-fold change in expression and coincided in M(IL-4) cells treated with PGE2 or Val (purple dots representing 24 genes in Figure 4B and 116 genes in Figure 4C , together totaling 126 non-overlapping genes). Retnla was among these, and its expression was downregulated by PGE2 and Val ( Figure 4B ). Flow cytometry confirmed that RELMa expression was suppressed by Val ( Figure 4D ) and FCCP (Figure S4B) , confirming Retnla as a VRG. Although induced RELMa production in M(IL-4) cells was typically low after viral transduction, we found that reduced GOT1 expression, which partially restored Dc m ( Figure 3J ), resulted in increased RELMa expression in PGE2-treated M(IL-4) macrophages ( Figure 4E ). Moreover, RELMa was increased in M(IL-4) cells after suppression of GOT1 expression ( Figure 4E ). This paralleled the effects of GOT1 suppression on Dc m in M(IL-4) macrophages ( Figure 3J ), providing support for a link between the MAS, Dc m , and RELMa expression. Ingenuity Pathway Analysis revealed that aspects of cell-cycle biology were enriched in the VRG set ( Figure S4C ). Specifically, multiple VRGs relate to the cell cycle and a signature induced by tunicamycin, which can lead to cell-cycle arrest ( Figure 4F ). This prompted us to explore the effects of PGE2 on macrophage proliferation. Macrophages proliferate after IL-4 stimulation (Jenkins et al., 2011) , and we found that, in vitro, EdU incorporation in M(IL-4) macrophages was reduced by approximately 40% (legend continued on next page) upon PGE2 co-stimulation ( Figures 4G and S4D) . We examined the effect of PGE2 on proliferation in vivo by using a system in which pMacs were collected, labeled with Cell Trace, treated with PGE2 in vitro for 6 hr (by which point Dc m was diminished), and then transferred by intraperitoneal injection into congenically marked mice ( Figure 4H ). Recipients were then injected with IL-4 complex (IL-4c) intraperitoneally, and 4 days later pMacsincluding those that had been transferred ( Figure S4E )-were recovered. As expected, the number of host CD45.2 + pMacs between the groups was comparable ( Figure S4F) ; however, the number and percentage of transferred CD45.1 + pMacs were reduced by PGE2 pre-treatment ( Figure 4I ). Moreover, pMacs treated with PGE2 underwent fewer divisions in response to IL-4c ( Figure 4J ). We hypothesized that reduced Dc m would restrict the initial expansion of pMacs. Consequently, we examined proliferation on day 2 and included a group treated with Val to directly implicate a loss of Dc m ( Figure 4K ). Both PGE2 and Val pre-treatment reduced the percentage of transferred pMacs found to be dividing after IL-4c injection ( Figure 4K ), demonstrating that loss of Dc m negatively affects macrophage proliferation in vivo. Our data support previous contentions that Dc m regulates the cell cycle (Martínez-Reyes et al., 2016) by showing that a set of cell-cycle-related genes are regulated by PGE2-induced changes in Dc m . Consistent with this, Dc m reductions driven by PGE2 or Val result in diminished cellular proliferation.
Multiple cell types express PGE2 receptors, and we were interested in whether the effects of PGE2 on macrophage Dc m , respiration, and proliferation would also be apparent in other immune cells. We examined the effects of PGE2 on naive CD8 + T cells stimulated with anti-CD3 plus anti-CD28 given that stimulation increases OXPHOS (Klein Geltink et al., 2017) and drives extensive proliferation. We found that PGE2 caused a reduction in Dc m ( Figure 4L ), basal OCR, maximal respiration ( Figure S4G ), and proliferation ( Figure 4M ), providing mechanistic insight into PGE2-mediated CD8 + T cell inhibition (Basingab et al., 2016) .
ETV-1 Is a Dc m -Sensitive Transcription Factor
Mitochondrial metabolism can alter chromatin accessibility through its effects on the acetylation of histones. Consequently, we asked whether PGE2 and Val alter the accessibility of regulatory regions in the loci of VRGs. Using the assay for transposaseaccessible chromatin using sequencing (ATAC-seq), we looked for shared changes in chromatin accessibility between cells treated with IL-4 plus PGE2 or plus Val. In this manner, we found 627 statistically supported genomic regions that exhibited a >2-fold change in chromatin accessibility in response to diminished Dc m ( Figures S5A and S5B ). Of these sites, 93% were less accessible upon treatment with PGE2 or Val ( Figure S5B ), supporting the view that suppressed mitochondrial metabolism negatively affects chromatin accessibility. Among them, we observed that at least two distinct sites in the Retnla loci were closed in resting macrophages but open in M(IL-4) macrophages and were made less accessible by PGE2 or Val ( Figure 5A , highlighted in purple). A consensus STAT6-binding site was found in one of these peaks ( Figure 5A , purple dotted line), providing a mechanistic basis for why this region of chromatin regulates RELMa expression. Thus, Dc m -induced reduction in chromatin accessibility could account for PGE2-and Val-induced changes in expression of Retnla. Nevertheless, of the VRGs, only Retnla and five additional loci (Fignl1, Ero1l, Zfp521, Gins1, and Tuba8, as shown in Figure S5C ) were regulated in this way, whereas other VRGs were not-for example, Wwc1, Osm, and Socs3 ( Figures 5B-5D ). Given the fact that for the majority of VRGs expression and chromatin accessibility were not correlated, we hypothesized that the mechanism linking Dc m to transcriptional regulation could be through the gain or loss of activation of specific TFs. To address this possibility, we identified TF binding sites within accessible chromatin in VRG promoter regions (defined as %20 kb upstream of transcription start sites) by reasoning that shared TF binding signatures could provide evidence for shared regulatory mechanisms. This footprint analysis identified enriched binding motifs for ETV1 ( Figure 5E ), FLI1, and KLF5 ( Figure S5D ). ETV1 was the most enriched of these in that it showed 103 potential binding sites in 84% of the identified VRGs, including Retnla, Wwc1, Osm, and Socs3 ( Figures 5A-5D , highlighted in green). Other TFs typically associated with PGE2 stimulation, such as CREB or Wnt signaling (Rodríguez et al., 2014) , were not enriched in these promoter sites.
On the basis of these findings, we reasoned that ETV1 might play a role in regulating expression of VRGs and therefore examined effects of loss or gain of function of Etv1 by using lentivirally delivered Etv1-specific shRNA ( Figure S5E ) or an shRNA-resistant V5-peptide-tagged ETV1 mutant (ETV1 V5 WT ), respectively, in M(IL-4) macrophages with and without PGE2. Compared with macrophages transduced with control shRNA, macrophages transduced with Etv1 shRNA reversed the effects of PGE2 on RELMa expression ( Figure 5F ). Moreover, Etv1 shRNA promoted RELMa expression beyond the amounts seen in cells stimulated with IL-4 alone ( Figure 5F ), marking ETV1 as a negative RELMa regulator that controls Retnla expression after Dc m reduction. Conversely, overexpressed ETV1 ( Figure S5F ), which was exclusively nuclearly localized under all stimulation conditions ( Figure S5G ), reverted the effects of Etv1-shRNA treatment and profoundly suppressed RELMa expression. We selected two additional VRGs in which the ETV1 motif was enriched, Socs3 and Osm, and found that effects of PGE2 on their expression was also reversed by Etv1 shRNA ( Figure 5G ). Likewise, gene expression changes in Retnla, Socs3, and Osm downstream of dissipation of Dc m with Val were reversed by Etv1 shRNA ( Figure 5H ). We then explored the global effects of Etv1 shRNA on gene expression via RNA sequencing (RNA-seq). Suppression of ETV1 expression had an effect in M(À) and M(IL-4) macrophages ( Figure 5I ) but had the biggest impact on (F-J) BMMs transduced with a control or Etv1 shRNA were stimulated with IL-4 ± PGE2 or ± Val (F-J). At 6 hr, RNA was extracted and tested by qRT-PCR for the indicated genes (F-H) or by RNA-seq (I and J). RELMa was assessed by flow cytometry after 24 hr (F). RNA-seq data from three biological replicates are presented as a principal component analysis (PCA), (I) and heatmap of 48 VRGs regulated (adjusted p value < 0.1, >2-fold change) by Etv1 shRNA in M(IL-4) cells treated with PGE2. In (I), arrows provide a measure for the magnitude of variation for each treatment, and in (J), genes associated with the cell cycle are in blue, and Retnla is in red. Error bars represent the mean ± SEM from three to eight biological replicates; *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001. See also Figure S5 . Figure 5I ). Indeed, effects of PGE2 on the expression of 48 out of 126 VRGs, including Retnla (in red) and five genes that had been earlier associated with the cell cycle (underlined in blue), were reversed by the suppression of Etv1 ( Figure 5J ). In light of this, we explored the role of ETV1 on macrophage proliferation and found that Etv1 shRNA negatively affects the incorporation of EdU + regardless of the presence or absence of PGE2 ( Figure S5H ), suggesting that this protein has a role in the cell cycle beyond the phenotype associated with Dc m . We sought an explanation for how ETV1 might respond to Dc m . Nuclear localization of ETV1 under all circumstances intimated that regulated movement into the nucleus is not responsible for Dc m -driven changes in ETV1 activity. On the basis of the known propensity of Ets-family TFs to interact with other proteins (Verger and Duterque-Coquillaud, 2002) , we explored the possibility that ETV1 activation is regulated by the association with a Dc m -sensitive partner that transfers information from mitochondria to the nucleus. We expressed ETV1 V5 WT in murine embryonic fibroblasts (MEFs) ( Figure S5I ) and used anti-V5 antibodies to immunoprecipitate ETV1 and any interacting proteins.
M(IL-4) cells treated with PGE2 (
As a negative control, we used identical conditions that included competing concentrations of V5 epitope peptide. Tryptic peptides from these immunoprecipitates were identified by mass spectrometry and compared with negative controls (false-discovery rate [FDR] = 1%) ( Figure S5J ). Retaining only proteins identified on the basis of two or more peptides and with at least 4-fold higher enrichment than the negative control, we identified ten proteins as interacting with ETV1 ( Figure S5J ). In this analysis, ETV1 was the most highly enriched protein, whereas no ETV1 peptides were detected in the negative controls (Figure S5J ). Among the interacting proteins was single-stranded DNA-binding protein (SSBP1), which is a mitochondrial protein linked directly to Dc m , which can dissociate from mitochondria (Jiang et al., 2016; Tan et al., 2015) . We postulate that SSBP1's acting in concert with ETV1 could serve to mediate Dc m -dependent effects on transcription. Altogether, our data show that PGE2 reduces Dc m and in turn leads to the altered expression of 126 VRGs, including Retnla. We have shown that ETV1 plays a role in the regulation of 38% of these VRGs, revealing ETV1 as a TF that, possibly through interaction with other proteins, detects changes in Dc m and revealing Dc m as a mediator of mitochondrial-directed nuclear gene expression.
DISCUSSION
The electrochemical gradient across the inner mitochondrial membrane is the force that drives mitochondrial ATP synthesis. This process is fueled by NADH and FADH 2 , which are made by the TCA cycle, and by mitochondrial shuttle systems, which balance redox between mitochondria and the cytoplasm. As we sought to understand the reported role of PGE2 on macrophage alternative activation, we uncovered the ability of PGE2 to alter immune cell function by regulating Dc m . Our data indicate that loss of Dc m after PGE2 treatment results from changes in MAS function and leads to the regulation of expression of 126 genes (the VRGs). For a minority of these genes, including Retnla, expression was associated with a Dc m -driven loss of chromatin accessibility. However, accessibility of binding sites for ETV1 was the dominant common feature underpinning VRG regulation, suggesting that ETV1 is a Dc m -sensitive TF. Our work reveals a previously unappreciated ability of PGE2 to regulate Dc m and a Dc m -based mechanism through which mitochondria are able to regulate nuclear gene expression.
We found that changes in expression of MAS genes, and in particular Got1, are in part responsible for the PGE2-induced decrease in Dc m . ATAC-seq coupled with TF enrichment analysis showed that MAS genes are likely to be regulated by AP-1 (data not shown), consistent with reports that PGE2 is able to promote gene expression by activating AP-1 in a cAMP-and PKA-mediated manner (Iwahashi et al., 2000) . We found that, consistent with altered MAS, amounts of NAD + , Glu, and Asp were reduced in PGE2-treated M(IL-4) macrophages. Glu has been implicated previously in M(IL-4) cell activation (Jha et al., 2015) , at least in part through the production of aKG . Increased aKG enhances the expression of M(IL-4) cell genes by promoting histone demethylation . Broadly consistent with this, our results show that the STAT6 binding site in the Retnla locus is made accessible by IL-4 treatment, a process that most likely requires histone demethylation, whereas PGE2 is able to block this chromatin-remodeling event.
Moreover, in addition to affecting Dc m , GOT1 has been found to affect DNA methylation by decreasing the ratio of aKG to 2-hydroxyglutarate (2-HG) (Xu et al., 2017) , a mechanism that could affect the Retnla locus, in addition to GOT1 effects on Dc m . On the basis of recent reports of the importance of Asp for cellular proliferation (Sullivan et al., 2015) , it is conceivable that reductions in the amount of this amino acid in PGE2-treated cells could contribute to the observed reduction in proliferative potential. Given the strong regulatory role of the MAS in M(IL-4) cells, the functional consequences of loss of function of other genes in the pathway warrant further study.
In the case of IL-4-stimulated macrophages, PGE2-mediated signaling has been reported to potentiate the STAT6-dependent gene signature via a CREB-dependent pathway (Luan et al., 2015) . Our data partially concur with these findings but differ in showing that Retnla expression is repressed by PGE2. We could recapitulate the effect of PGE2 on RELMa by using 8-Br-cAMP and forskolin, thereby reinforcing the view that PGE2 and associated signaling events negatively affect RELMa expression. Moreover, our transcriptomic analysis revealed that it is an over-simplification to say that PGE2 enhances or inhibits alternative activation; rather, our data show that PGE2 broadly modified the effects of IL-4. Functionally, RELMa has been shown to induce the expression of lysyl hydroxylase 2 in fibroblasts, which induces collagen crosslinking, a process that is important for tissue repair, but which in excess can contribute to fibrosis (Knipper et al., 2015) . In this context, it is possible to speculate that the reported regulatory effects of PGE2 on fibrosis (Harada et al., 2017) are linked to its ability to suppress RELMa expression.
Our conclusion that PGE2-induced loss of Dc m affects nuclear gene expression in M(IL-4) macrophages is based on our use of Val as a distinct, parallel approach to dissipating Dc m . Val treatment emphasizes the role of Dc m and not other mechanisms of mitochondrial-nuclear communication. It causes an acute loss of Dc m in the absence of secondary effects resulting from complete mitochondrial DNA depletion (as seen in r0 cells [Martínez-Reyes et al., 2016] ) or plasma-membrane depolarization (as seen with FCCP [Kenwood et al., 2013] ). Unlike M(IL-4) macrophages treated with PGE2, M(IL-4) microphages treated with Val had higher amounts of ROS and higher amounts of NAD + than M(IL-4) controls (data not shown), making it unlikely that changes in ROS or NAD + abundance per se explain the overlapping effects of PGE2 and Val. However, the similar effect of PGE2 and Val provides a mechanistic link between Dc m and the distinct VRG expression signature. Our data show that regulatory regions around VRGs are enriched with binding sites for the Ets-family TF ETV1. ETV1 is known to regulate neurogenesis (Bartel et al., 2000) , repress the expression of cell-cycle regulators (Lunardi et al., 2015) , and be implicated in various cancers (Oh et al., 2012) . To the best of our knowledge, ETV1 has not been linked to immune cell function, yet our genetic loss-and gain-of-function experiments show that it has marked effects on macrophage biology, particularly on the expression of RELMa. We have made initial steps to understand how ETV1 is regulated by Dc m . Consistent with its annotation in curated databases (UniProt: P41164), we found ETV1 to be inherently nuclearly localized. With the caveat that we used an overexpression vector, this intimates that regulated movement between the cytoplasm and nucleus is not responsible for Dc m -driven changes in ETV1 activity. Ets proteins are recognized to have extensive interactions with other TFs (Verger and DuterqueCoquillaud, 2002) . Therefore, we reasoned that an interacting partner could confer Dc m sensitivity on ETV1. Using mass spectrometry, we identified a set of ETV1-interacting partners, one of which was SSBP1. Previous studies have shown SSBP1 to translocate from mitochondria to the nucleus and alter nuclear gene transcription during mitochondrial stress (Tan et al., 2015) . Thus, it is conceivable that in the context of decreased Dc m , SSBP1 translocates from the mitochondria to the nucleus and alters ETV1 activity. Our studies to address the role of PGE2 in alternative macrophage activation led us to the discovery that PGE2 is able to affect mitochondrial biology by lowering Dc m . We linked this PGE2-mediated effect to induced changes in the MAS. We found that changes in Dc m can in turn affect the expression of a set of genes transcriptionally regulated by ETV1. Our data indicate that in addition to more widely understood mitochondrial mechanisms that can affect nuclear gene expression, the transcriptional activity of ETV1 can be regulated by Dc m . Future work will attempt to further elucidate underlying mechanisms controlling this process.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Professor Edward James Pearce (pearceed@ie-freiburg.mpg.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Models C57BL/6J (RRID: IMSR_JAX:000664) and CD45.1 congenic (RRID: IMSR_JAX:002014) mouse strains were purchased from The Jackson Laboratory, maintained at the Max Planck Institute for Immunobiology and Epigenetics and cared for according to the Institutional Animal Use and Care Guidelines with approval by the animal care committee of the Regierungspraesidium Freiburg, Germany. All animals used for tissue harvest or experimental procedures were female and aged between 6-7 weeks at the start of the experiment. Animals were humanely sacrificed by carbon dioxide asphyxiation followed by cervical dislocation and bone marrow, peritoneal lavage or spleens were harvested. Mice were bred under specific pathogen free standards, and transferred to open top cages for experimental procedures.
Primary cell cultures
Mature BMMs were obtained at day 7 of culture of bone marrow cells in 20 ng/mL CSF-1 (Peprotech) in RPMI medium containing 10% fetal bovine serum, 4 mM L-glutamine, 100 U/mL penicillin and streptomycin (complete RPMI) (all GIBCO). BMMs were stimulated in complete RPMI supplemented with CSF-1 for indicated times with a combination of 20 ng/mL IL-4 (Peprotech), 10 mM PGE2 (SIGMA), 100 mM 8-Br-cAMP (Peprotech), 20 mM Forskolin (Peprotech), 50 ng/mL IFN-g (Peprotech), 20 ng/mL LPS (SIGMA), 100 mM Ap5a (SIGMA), 1.5 mM flurorcarbonyl cyanide phenylhydrazon (FCCP -SIGMA), 10 nM valinomycin (SIGMA), 10 mM EdU (Life Technologies), 10 mM KT5720 (TOCRIS), 10 mM H-89 (SIGMA) or 2 mM a-amanitin (SIGMA) under 5% CO2, atmospheric oxygen, at 37 C in a humidified incubator. In specific experiments, glucose-free complete RPMI was used, supplemented with 10 mM Glucose (SIGMA), 10 mM fully labeled 13 C-Glucose (Euroiso-top) or 10 mM singly deuterated 2 H-Glucose (SIGMA).
Peritoneal macrophages were obtained by performing a peritoneal lavage on naive animals with 2% fetal bovine serum (GIBCO) in PBS. Cells were counted, plated in complete RPMI supplemented with CSF-1 and selected based on adherence. Stimulation was performed using the same conditions as with BMMs.
Naive CD8 + T cells were obtained from total splenocytes using the naive CD8 T cell isolation kit (Stem Cell technologies) according to the manufacturers protocol. In specific experiments isolated T cells were stained with CFDA-SE Cell Tracer (Thermo Fisher Scientific) following the manufacturer's protocol. T cells were then activated using plate bound 5 mg/mL anti-CD3 (clone: 17A2, BioLegend) plus soluble 0.5 mg/mL anti-CD28 (clone: 37.51, BioLegend) in complete RPMI supplemented with 100 U/mL hrIL-2 (Peprotech), 55 mM beta-mercaptoethanol, under 5% CO2, atmospheric oxygen, at 37 C in a humidified incubator. Fresh buffy coats from healthy donors were collected from the Blood Donation Center of the University Hospital Freiburg, under approval by the ethical committee of the University of Freiburg. Researchers were blinded to the identity of the donors, and age or sex matching was not performed. Sample size is indicated in the figure legends.
Cell lines HEK293T/17 cells and NIH 3T3 MEFs (all ATCC) were maintained in DMEM containing 10% fetal bovine serum, 4 mM L-glutamine, 100 U/mL penicillin and streptomycin (all GIBCO) under 5% CO2, atmospheric oxygen, at 37 C in a humidified incubator.
METHOD DETAILS
RNA-seq
BMMs were stimulated and total RNA was extracted with the RNAqueous-Micro Total RNA Isolation Kit (Thermo Fisher Scientific) and quantified using Qubit 2.0 (Thermo Fisher Scientific) following the manufacturer's instructions. Libraries were prepared using the TruSeq stranded mRNA kit (Illumina) and sequenced in a HISeq 3000 (Illumina) by the Deep-sequencing Facility at the MaxPlanck-Institute for Immunobiology and Epigenetics. Sequenced libraries were processed using STAR (Dobin et al., 2013) , for trimming and mapping, and featureCounts (Liao et al., 2014) to quantify mapped reads. Raw mapped reads were processed in R (Lucent Technologies) with DESeq2 , to determine differentially expressed genes and generate normalized read counts to visualize as heatmaps using Morpheus (Broad Institute). Pathway enrichment analysis was performed using Ingenuity Pathway Analysis (QIAGEN), which makes predictions using pairwise comparisons between conditions, incorporating in the analysis the statistically significant changes in expression within each of those comparisons.
Flow cytometry
Used fluorochrome-conjugate monoclonal antibodies included: CD301 (Milteny Biotech, clone: REA687), CD11b (Biolegend, clone: M1/70), F4/80 (Biozol, clone: BM8), TIM4 (BioLegend, clone: F31-5G3), CD45.1 (BioLegend, clone: A20). Staining was performed in 1% fetal bovine serum in PBS for 30 min on ice, including anti-CD16/CD32 (Biozol); dead cells were excluded with the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Thermo scientific). For intracellular RELMa staining, cells were processed with the Transcription Factor Staining Buffer Set (Thermo Fisher Scientific) following the manufacturer protocol. RELMa primary antibody staining (Peprotech Cat# 500-P214) was detected using Alexa Fluor-421 anti-rabbit secondary antibody (Life technologies). Tagged ETV1 were labeled using a monoclonal anti-V5 antibody (Life Technologies, RRID: AB_2556564) and detected with an anti-Mouse IgG2a PE secondary (eBioscience). EdU staining was performed using the Click-iTÒ EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Thermo Fisher Scientific) according to the manufacturer's protocol. Dead and Apoptotic cells were detected using Annexin V, Alexa Fluor 550 conjugate (Thermo Fisher Scientific) following the manufacturer's protocol. Cells were analyzed using LSR Fortessa flow cytometers (BDBiosciences) and data were processed using FlowJo software (FlowJo).
Metabolic assays
Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were measured using the 96 well Extracellular Flux Analyzer (Seahorse Bioscience). 1x10 5 BMMs exposed to different treatments or 2x10 5 T cells were spun onto each well of seahorse X96 cell culture microplates (coated with poly-D-lysine for T cell assays) and preincubated at 37 C for a minimum of 45 min in the absence of CO 2 in un-buffered RPMI with 25 mM glucose, 1 mM pyruvate and 2 mM L-glutamine with pH adjusted to 7.4. For long T cell assays (> 8 h) media was supplemented with 100 U/ml hrIL-2 (Peprotech). For activation of T cells, anti-CD3 + anti-CD28 coated beads were used at 1:1 ratio of beads:T cells. OCR and ECAR were measured under basal conditions, after activation, and after the addition of the following drugs: 1 mM oligomycin, 1.5 mM flurorcarbonyl cyanide phenylhydrazon (FCCP) and 100 nM rotenone + 1 mM antimycin A (all SIGMA) as indicated. Results were collected with Wave software version 2.4 (Agilent).
For metabolic tracing and metabolite quantitation BMMs stimulated as described above were cultured in glucose-free media supplemented with 10 mM 13 C-glucose (Euroiso-top) for 6 hr or 24 hr, or supplemented with 10 mM 2 H-glucose (SIGMA) for 10 min. Cells were washed with ice cold 0.9% (w/v) NaCl buffer and metabolites were extracted twice with Methanol (80%) and analyzed by Liquid chromatography (Agilent 1290 infinity II UHPLC) coupled to tandem mass spectrometry (Agilent 6495B), or by Gas chromatography coupled to tandem mass spectrometry (Agilent 5977) by the Metabolomics Core, Max-Plank-Institute for Immunobiology and Epigenetics, Freiburg, Germany or with a Thermo Scientific Q Exactive mass spectrometer coupled to a UltiMate 3000 UPLC chromatography system at the University of California -Los Angeles Metabolomics Centre, Los Angeles, USA.
Glucose uptake, mitochondrial content, cellular ROS and mitochondrial ROS were measured by incubating with 100 nM 2NBDG for 2 min, 100 nM MitoTracker Green for 30 min, 5 mM CellROX deep red for 30 min, all in complete medium, 5 mM MitoSOX for 10 min in HBSS, all at 37 C (all Thermo Fisher Scientific), respectively. Cells were then cooled on ice and analyzed using LSR Fortessa flow cytometers (BDBiosciences) and data were processed using FlowJo software (FlowJo). For ATP measurements, cells were resuspended in water (1000 cells/mL), boiled for 10 min at 95 C and then lysates were analyzed with the ATP determination kit (Thermo Fisher Scientific) following the manufacturer's instructions.
Mitochondrial membrane potential was measured by incorporation of Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM) (Thermo Fisher Scientific) into living cells. Cells were incubated for 30 min at 37 C with 50 nM TMRM with and without 15 mM FCCP. Cells were then washed and analyzed by flow cytometry in the presence of 2 mg/mL DAPI as a viability exclusion dye. For real time measurement of ETC complex activity, BMMs were harvested after 24 h stimulation and placed in a solution containing 220 mM mannitol, 70 mM sucrose, 10 mM KH 2 PO 4 , 5 mM MgCl 2 , 2 mM HEPES, 1 mM EGTA and 0.2% (w/v) bovine serum albumin (all SIGMA) with 50 nM TMRM and 1 nM Agilent Seahorse XF Plasma Membrane Permeabilizer (Agilent). For real time CV measurements cells were maintained in complete media and then treated with 1 mM oligomycin and later 15 mM FCCP. Cells were analyzed using LSR Fortessa flow cytometers (BDBiosciences) and data were processed using FlowJo software (FlowJo). For real time measurements, cells were maintained at 37 C using a custom built sample holder, and treated sequentially with 100 nM rotenone, 10 mM sodium succinate, 1 mM antimycin A (all Sigma) as indicated.
Confocal Microscopy
Macrophages were cultured for 6 hr or 24 hr as described above on glass coverslips, then stained with 100 nM MitoTracker Deep Red (Thermo Fisher Scientific) for 30 min at 37 C, then washed, briefly incubated with 2 mg/mL DAPI (Thermo Fisher Scientific) and then fixed with 4% formaldehyde (SIGMA). In selected experiments, cells were permeabilized and then stained in 0.05% Saponin (SIGMA) and 0.2% BSA with anti-V5 antibody detected with anti-mouse AF546 (all Life Technologies). Coverslips were mounted on slides using ProLong Diamond (Thermo Fisher Scientific) and left to settle at 4 C overnight. LSM 880 Airyscan microscope (Zeiss) was used to acquire confocal images. Confocal images were acquired with ZEN software (Zeiss), deconvolved with HuygensSoftware, and analyzed using Imaris imaging software.
Electron Microscopy 1 3 10 6 BMMs were fixed in 2.5% glutaraldehyde (SIGMA) in 100 mM sodium cocodylate (SIGMA) then washed in cocodylate buffer.
Following this step, samples were processed and imaged at the Electron Microscopy Laboratory at the University of Padova. After dehydration samples were embedded in Eponate 12 resin (Ted Pella) and sections were cut. Images were acquired using a FEI Tecnai 12 Transmission electron microscope equipped with a TIETZ digital camera. Maximal cristae width was measured using ImageJ software and averaged over 50 independent images. 2018) with modifications detailed in the following. QExactive mass spectrometer and Easy nanoLC-1000 were employed for all experiments. Tryptic peptides were separated by a 2h linear gradient of 5%-80% buffer B (80% acetonitrile, 0.1% formic acid) at constant flowrate of 300 nL/min. For MS data acquisition the ''sensitive'' method from Kelstrup et al. (Kelstrup et al., 2012 ) was adopted. MS raw files were analyzed by MaxQuant software (1.5.7.4) and peak lists were searched against the mouse Uniprot FASTA (October 2017) database (concatenated with a database containing common contaminants) by the Andromeda search engine embedded in MaxQuant (Cox and Mann, 2008; Cox et al., 2011) . MS1-based label free quantification (LFQ) was done using maxLFQ algorithm (Cox et al., 2014) . We require a minimum of two peptide ratios in order to consider a given protein as valid (protein and peptide ID FDR = 0.01). Perseus platform (Tyanova et al., 2016 ) was used to perform data normalization, filtering, and statistical testing. Student's t test was utilized to define differentially expressed proteins employing a 4-fold change as a cut-off at a 1% FDR. Negative IP control replicates and IP sample triplicates were measured twice on the mass spectrometer, and the resulting 4 or 6 datasets respectively used to calculate protein enrichment across the IP samples.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using prism 6 software (Graph pad) and results are represented as mean ± SEM, unless otherwise indicated. Comparisons for two groups were calculated using unpaired two-tailed Student's t tests, comparisons of more than two groups were calculated using one-way ANOVA with Sidak's correction for multiple comparison tests. Comparisons between materials from human biopsies, were analyzed with paired two-tailed Student's t tests. We observed normal distribution and no difference in variance between groups in individual comparisons. Selection of sample size was based on extensive experience with metabolic assays.
DATA AND SOFTWARE AVAILABILITY
Next generation sequencing data can be accessed at Gene Ontology Omnibus under GEO: GSE119521. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PRIDE: PXD010997.
